Citigroup
ARIA

Citigroup’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Citigroup’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-777,786
Closed -$9.68M – 7518
2016
Q4 		$9.68M Buy
777,786
+692,567
+813% +$8.34M 0.01% 1220
2016
Q3 		$1.17M Buy
85,219
+40,730
+92% +$409K ﹤0.01% 3059
2016
Q2 		$329K Sell
44,489
-83,398
-65% -$626K ﹤0.01% 4052
2016
Q1 		$818K Buy
127,887
+95,506
+295% +$535K ﹤0.01% 3574
2015
Q4 		$203K Sell
32,381
-82,347
-72% -$540K ﹤0.01% 4738
2015
Q3 		$671K Buy
114,728
+75,543
+193% +$582K ﹤0.01% 3460
2015
Q2 		$323K Sell
39,185
-13,694
-26% -$121K ﹤0.01% 4076
2015
Q1 		$436K Sell
52,879
-30,386
-36% -$225K ﹤0.01% 3877
2014
Q4 		$572K Buy
83,265
+75,210
+934% +$470K ﹤0.01% 3747
2014
Q3 		$43K Sell
8,055
-75,442
-90% -$441K ﹤0.01% 5418
2014
Q2 		$531K Buy
83,497
+27,818
+50% +$191K ﹤0.01% 3433
2014
Q1 		$449K Buy
55,679
+33,621
+152% +$262K ﹤0.01% 3577
2013
Q4 		$150K Sell
22,058
-57,172
-72% -$309K ﹤0.01% 4913
2013
Q3 		$1.46M Buy
79,230
+65,267
+467% +$1.27M ﹤0.01% 2649
2013
Q2 		$244K Buy
+13,963
New +$248K ﹤0.01% 4105

Other funds holding ARIA

FPF
FNY Partners Fund New York $185M AUM 32.57% 1-Year Est. Return

Citigroup's ARIA Position: Q1 2017 in Review

Citigroup sold out of Ariad Pharmaceuticals Inc (ARIA) in Q1 2017, closing a stake of 777,786 shares — an estimated $9.68M sold.

Citigroup first reported a position in ARIA in Q2 2013 and held it in 15 quarters. The position peaked at $9.68M in Q4 2016. 1 fund tracked by Wall St. Rank holds ARIA as of Q1 2017.

  • Citigroup reported no remaining Ariad Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
  • Citigroup sold 777,786 Ariad Pharmaceuticals Inc shares in Q1 2017, an estimated $9.68M.
  • Citigroup first reported a position in Ariad Pharmaceuticals Inc in Q2 2013 and held it in 15 quarters.
  • Citigroup's Ariad Pharmaceuticals Inc position peaked at $9.68M in Q4 2016.
  • 1 fund tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q1 2017.

Based on Citigroup's 13F filing for Q1 2017, filed 12 May 2017.